Annovis Bio, Inc.
(NYSE : ANVS)

( )
ANVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.00%54.950.9%$2134.82m
JNJJohnson & Johnson -0.02%167.800.7%$981.75m
ABBVAbbVie, Inc. 0.02%135.891.9%$880.45m
MRKMerck & Co., Inc. -0.01%81.370.7%$851.92m
BMYBristol-Myers Squibb Co. 0.03%64.951.0%$676.65m
LLYEli Lilly & Co. 0.01%244.151.1%$623.70m
AZNAstraZeneca Plc 0.00%58.851.0%$232.31m
NVSNovartis AG 0.01%90.560.2%$204.60m
NVONovo Nordisk A/S 0.02%96.340.1%$165.68m
VTRSViatris, Inc. 0.00%15.220.0%$148.94m
GSKGlaxoSmithKline Plc 0.00%45.470.2%$142.24m
RGENRepligen Corp. 0.00%193.266.7%$98.44m
IMMXImmix Biopharma, Inc. 0.00%5.840.0%$95.50m
ALLKAllakos, Inc. 0.00%7.640.0%$93.56m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.14%122.000.0%$74.51m

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.